Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

Advances in Therapy - United States
doi 10.1007/s12325-019-01186-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cladribine for Highly Active Relapsing Multiple Sclerosis

Prescriber
Pharmacology
2018English

Pnd26 - Cost Implications of a Novel Weight Dosed Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd65 - Cost-Effectiveness Analysis of Drugs Used for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd27 - Cost Implications in the Selection of First Line Treatment for Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd62 - Cost-Effectiveness of Cladribine Tablets in the Treatment of Patients With Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Natalizumab Therapy for Highly Active Pediatric Multiple Sclerosis

JAMA Neurology
Neurology
2013English

Pnd29 - Long Range Simulation of the Cost Burden of Difference Treatment Sequences Approved for the Treatment of Highly Active Relapsing Multiple Sclerosis in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd73 - The Impact of Modelling Subsequent Treatment on Estimates of Cost-Effectiveness: An Analysis of Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Emerging Therapies for Relapsing Multiple Sclerosis

Archives of Neurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy